FOR US HEALTHCARE PROFESSIONALS

For the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

Resources for AURYXIA

Find helpful resources including videos, brochures, and more.

Mechanism of Action

See how AURYXIA, an oral iron tablet, works in adult patients with iron deficiency anemia.

A Team Approach to Treating Iron Deficiency Anemia

Find out why these health care professionals choose AURYXIA for their adult patients with iron deficiency anemia not on dialysis.1

Access Support

Explore AURYXIA coverage specific to this indication.

Access SupportDOWNLOAD

AURYXIA Clinical Facts

Find out more about iron deficiency anemia and AURYXIA efficacy, safety, and access information.

AURYXIA Clinical FactsDOWNLOAD

AURYXIA Patient Handout

Help patients understand iron deficiency anemia and what to expect now that they have been prescribed AURYXIA.

AURYXIA Patient HandoutDOWNLOAD

Iron Deficiency Anemia Patient Handout

Give patients the important facts about iron deficiency anemia, some of the symptoms, possible treatment options, and more.

Iron Deficiency Anemia Patient HandoutDOWNLOAD

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS
The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

INDICATION

AURYXIA® (ferric citrate) is indicated for:

  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information

REFERENCE

  1. AURYXIA® [Package Insert]. Cambridge, MA: Akebia Therapeutics, Inc.; 2021.